Aldeyra The (ALDX) Stock Score, Valuation & Financial Research

Aldeyra The is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ALDX

Aldeyra The does not currently have a complete Wall Street Score. The stored market price is USD 1.23. These figures are a research snapshot, not a buy or sell recommendation.

What Aldeyra The does

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Aldeyra Therapeutics is a clinical-stage biotechnology company that does not currently generate product revenue. Its business model relies on financing its research and development activities through equity offerings, debt financings, and potential future collaboration, licensing, or marketing agreements.

Products and services

  • The company is a clinical-stage biotechnology firm focused on developing innovative therapies for immune-mediated diseases, including candidates such as reproxalap for dry eye disease.

Business strengths to evaluate

  • Clinical-stage pipeline focused on immune-mediated diseases Source

Business risks and research considerations

  • History of operating losses and no product revenue Source
  • Dependence on additional funding to continue operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ALDX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.23
Market capitalization:
74.19M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -23.05M
Free cash flow:
USD -33.35M
Cash:
USD 45.09M
Total debt:
USD 143.45K
EPS:
USD -0.39

What stands out

  • Free cash flow is USD -33.35M, negative for the stored period.
  • The balance sheet shows USD 45.09M of cash versus USD 143.45K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 44.95M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ALDX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ALDX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ALDX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ALDX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of ALDX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ALDX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.